Related Experiment Video

Updated: Jul 3, 2026

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level
05:35

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level

Published on: January 19, 2024

Growth in non-anemic infants supplemented with different prophylactic iron doses

Danielle G Silva1, Sylvia do C C Franceschini, Dirce M Sigulem

  • 1Universidade Federal de São Paulo - Escola Paulista de Medicina (UNIFESP-EPM), São Paulo, SP, Brazil. daniellegoes@ufs.br

Jornal De Pediatria
|August 9, 2008
PubMed

Insights

Different prophylactic iron doses did not impact the growth or nutritional status of non-anemic infants. This study found no significant differences in weight, length, or morbidity across various iron supplementation regimens.

Area of Science:

  • Pediatric Nutrition
  • Iron Metabolism
  • Infant Growth and Development

Background:

  • Iron deficiency is a global health concern, impacting infant development.
  • Prophylactic iron supplementation is common, but optimal dosing for non-anemic infants remains debated.
  • Understanding the effects of different iron doses is crucial for public health guidelines.

Purpose of the Study:

  • To evaluate the impact of varying prophylactic iron doses on the growth and nutritional status of non-anemic infants.
  • To compare the efficacy of daily versus weekly iron supplementation regimens.
  • To assess the influence of iron dosing on infant morbidity.

Main Methods:

  • A prospective randomized study involving 114 non-anemic infants aged 5.0 to 6.9 months.
  • Infants were allocated to receive iron (ferrous sulfate) at 1 mg/kg/day, 2 mg/kg/day, or 25 mg/week for 16 weeks.
  • Anthropometric measurements (weight, length) and World Health Organization (WHO) z-scores were used to assess nutritional status; morbidity was monitored monthly.

Main Results:

  • Baseline nutritional status and daily nutrient intake were similar across all groups.
  • No statistically significant differences were observed in weight gain, length gain, or changes in anthropometric indices among the iron-supplemented groups.
  • The incidence and duration of morbidity episodes did not differ significantly between the groups.

Conclusions:

  • Prophylactic iron supplementation with different doses (1 mg/kg/day, 2 mg/kg/day, 25 mg/week) showed no differential effects on the growth and nutritional status of non-anemic infants.
  • Current prophylactic iron dosing strategies do not appear to significantly alter key growth parameters or health outcomes in this population.
  • Further research may explore long-term implications or specific subpopulations.
Abstract

More Related Videos

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes08:45

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay05:08

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

Published on: January 31, 2022

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...